Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of “Hold” from Analysts

Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) have been assigned an average rating of “Hold” from the five ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $15.00.

A number of equities research analysts have weighed in on IMMX shares. Wall Street Zen raised Immix Biopharma from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday, January 22nd. Citizens Jmp began coverage on Immix Biopharma in a report on Monday. They issued a “market outperform” rating and a $23.00 price target for the company. Finally, Mizuho initiated coverage on Immix Biopharma in a research note on Monday, February 9th. They issued an “outperform” rating and a $14.00 price target on the stock.

Immix Biopharma Stock Up 8.8%

Shares of NASDAQ:IMMX opened at $9.29 on Monday. Immix Biopharma has a fifty-two week low of $1.34 and a fifty-two week high of $9.47. The firm’s 50-day simple moving average is $6.38 and its 200-day simple moving average is $4.50. The company has a market cap of $492.00 million, a price-to-earnings ratio of -12.06 and a beta of 0.25.

Institutional Investors Weigh In On Immix Biopharma

Several institutional investors have recently made changes to their positions in IMMX. Kera Capital Partners Inc. purchased a new position in shares of Immix Biopharma in the fourth quarter valued at $68,000. Virtu Financial LLC acquired a new stake in Immix Biopharma in the 4th quarter valued at about $386,000. KVP Capital Advisors LP acquired a new stake in Immix Biopharma in the 4th quarter valued at about $1,205,000. XTX Topco Ltd increased its holdings in Immix Biopharma by 32.0% during the 4th quarter. XTX Topco Ltd now owns 46,394 shares of the company’s stock valued at $243,000 after acquiring an additional 11,241 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new position in Immix Biopharma during the 4th quarter valued at about $116,000. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.